Publications by authors named "D Boggiani"
Article Synopsis
- * These genes are critical for maintaining genetic integrity through homologous recombination (HR) DNA repair, which fixes DNA double-strand breaks effectively.
- * The review discusses the role of HR and its impact on the efficacy of poly (ADP-ribose) polymerase (PARP) inhibitors as a treatment, while also exploring the genetic factors and risk assessment approaches that could enhance strategies for prevention and treatment of these cancers.
Background: HER2-positive breast cancers are rare amongst BRCA mutation carriers. No data exist regarding clinicopathological characteristics and prognosis of this subgroup of patients.
Materials And Methods: Using a retrospective matched cohort design, we collected data from 700 women who were diagnosed with operable invasive breast cancer from January 2006 to December 2016 and were screened for germline BRCA mutations.
Women with pathogenic germline mutations in and genes have an increased risk to develop breast and ovarian cancer. There is, however, a high interpersonal variability in the modality and timing of tumor onset in those subjects, thus suggesting a potential role of other individual's genetic, epigenetic, and environmental risk factors in modulating the penetrance of BRCA mutations. MicroRNAs (miRNAs) are small noncoding RNAs that can modulate the expression of several genes involved in cancer initiation and progression.
View Article and Find Full Text PDFBackground: The combination of a microtubule inhibitor (eribulin) with a nucleoside analog (gemcitabine) may synergistically induce tumor cell death, particularly in triple negative breast cancer (TNBC) characterized by high cell proliferation, aggressive behavior, and chemo-resistance.
Patients And Methods: This is an open-label, multicenter phase II study evaluating the combination of eribulin (0.88 mg/m) plus gemcitabine (1000 mg/m) on days 1 and 8 of a 21-day cycle as either first- or second-line treatment of locally advanced or metastatic TNBC.